

TEXT

MAUPIN 09/835,371

=> D HIS

(FILE 'HOME' ENTERED AT 10:17:18 ON 05 JUL 2002)

FILE 'HCAPLUS' ENTERED AT 10:17:26 ON 05 JUL 2002
L1 202 S UHLMANN E?/AU
L2 105 S BREIPOHL G?/AU
L3 95 S WILL W?/AU
L4 377 S L1-3
L5 69 S POLYNUCLEIC ACID
L6 0 S L4 AND L5
L7 134728 S POLYAMIDE
L8 14 S L4 AND L7
L9 8 S L8 AND POLYAMIDE/TI
SELECT RN L9 1-8

inventor
search

FILE 'REGISTRY' ENTERED AT 10:21:17 ON 05 JUL 2002
L10 76 S E1-76

FILE 'HCAPLUS' ENTERED AT 10:21:54 ON 05 JUL 2002
L11 5 S L9 AND L10
L12 8 S L11 OR L9 *8 citations w/ 76 cpts displayed*
L13 6 S L8 NOT L9
L14 5523 S PNA OR NUCLEOPOLYPEP? OR POLYAMIDO(W)OLIGO? OR PEPTIDE(W)NUCL
L15 5592 S L5 OR L14
L16 2710 S ?PHOSPH?(5A) BACKBONE
L17 27 S L7 AND L16
L18 25 S L17 NOT L12
L19 17 S L18 AND (?PHOSPHORYL? OR ?PHOSPHAT?)
L20 15 S L18 AND (?PHOSPHORYL? OR ?PHOSPHAT?)/TI,AB
L21 2176 S ?PHOSPH?(2A) BACKBONE
L22 13 S L21 AND L20
SELECT RN L22 1-13

FILE 'REGISTRY' ENTERED AT 10:39:55 ON 05 JUL 2002
L23 101 S E77-177
L24 8 S L23 AND (P AND N)/ELS
L25 93 S L23 NOT L24
L26 0 S L25 AND P/ELS
L27 61 S L25 AND N/ELS

FILE 'HCAPLUS' ENTERED AT 10:44:43 ON 05 JUL 2002
L28 5 S L22 AND L27
L29 13 S L22 OR L28 *13 cites w/ 61 cpts displayed*
L30 62 S L16(P)L15
L31 50 S L30 NOT L17
L32 26 S L30 NOT REPLAC?/AB
L33 3 S L32 AND POLYAMID?
L34 112 S L16(3A) (HAVING OR HAS OR INCLUD?)
L35 16 S L15 AND L34
L36 13 S L35 AND (?PHOSPHORYL? OR ?PHOSPHAT?)
L37 2 S L36 NOT REPLAC?/AB
L38 13 S L32 AND (?PHOSPHORYL? OR ?PHOSPHAT?)
L39 10 S L38 NOT (SUBSTITUT? OR REPALC? OR EXCHANG?)
L40 9 S L39 NOT LACK?
L41 7 S L40 NOT MODIF?
L42 1 S L41 AND PREPAR?
L43 1 S L42 NOT L12 *1 cite w/ 63 cpts displayed* } grp is replaced by poly amido

} trying to get rid of
cites where phosph.

TEXT

MAUPIN 09/835,371

Inventor search

=> d ibib abs hitstr 1

L12 ANSWER 1 OF 8 HCPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:745539 HCPLUS
DOCUMENT NUMBER: 130:66670
TITLE: PNA: synthetic **polyamide** nucleic acids with unusual binding properties
AUTHOR(S): Uhlmann, Eugen; Peyman, Anusch;
Breipohl, Gerhard; Will, David W.
CORPORATE SOURCE: Hoechst Marion Rouseel Deutschland GmbH, Frankfurt am Main, D-65926, Germany
SOURCE: Angewandte Chemie, International Edition (1998), 37(20), 2796-2823
CODEN: ACIEF5; ISSN: 1433-7851
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 160 refs. : since the investigation of oligonucleotides as potential therapeutics that target nucleic acids was initiated, the search for nucleic acid mimetics with improved properties, such as strengthened binding-affinity to complementary nucleic acids, increased biol. stability, and improved cellular uptake, has accelerated rapidly. In 1991 Nielsen et al. first described what is undoubtedly one of the most interesting of the new derivs., the **polyamide** or peptide nucleic acids (PNAs), in which the entire sugar-phosphate backbone is replaced by an N-(2-aminoethyl)glycine **polyamide** structure. Since even minor structural changes in oligonucleotides, such as the replacement of an oxygen atom by sulfur (phosphorothioates), or by a neutral Me group (Me phosphonates), result in a decrease in binding affinity, it was even more astonishing to find that the drastic structural changes in PNAs result in nucleic acid mimetics with higher binding-affinity to complementary DNA and RNA than unmodified oligonucleotides. The remarkable binding properties of PNAs have spawned a rapidly expanding new field of research, where the targets are the synthesis of PNAs and PNA analogs, and their application as therapeutics, DNA diagnostics, and tools in biotechnol. In add., investigation of PNAs and PNA/DNA chimeras can be used to generate information on the structural and biol. properties of DNA and RNA themselves. Furthermore, they may trigger the generation of new ideas on models for alternative living systems and potential transitions between different genetic systems.
REFERENCE COUNT: 171 THERE ARE 171 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 2

L12 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1997:591221 HCAPLUS
 DOCUMENT NUMBER: 127:262910
 TITLE: Synthesis of **polyamide** nucleic acids (PNAs),
 PNA/DNA-chimeras and phosphonic ester nucleic acids
 (PHONAs)
 AUTHOR(S): Uhlmann, E.; Will, D. W.; Breipohl,
 G.; Peyman, A.; Langner, D.; Knolle, J.;
 O'Malley, G.
 CORPORATE SOURCE: Central Pharma Res., Hoechst AG, Frankfurt, D-65926,
 Germany
 SOURCE: Nucleosides & Nucleotides (1997), 16(5 & 6), 603-608
 CODEN: NUNUD5; ISSN: 0732-8311
 PUBLISHER: Dekker
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review with 18 refs. on methods for the prepn. of **polyamide**
 nucleic acids (PNAs) and derivs. thereof by different synthetic routes is
 described. The first strategy makes use of 9-Fluorenylmethoxycarbonyl
 (Fmoc)/monomethoxytrityl (Mmt) protected building blocks, whereas the
 second approach involves the use of Mmt/acyl protected monomers, which
 allows the prepn. of PNA/DNA chimera. Addnl., a block coupling strategy
 is presented for the synthesis of novel phosphonic ester nucleic acids
 (PHONAs).

=> d ind 2

L12 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2002 ACS
 CC 33-0 (Carbohydrates)
 Section cross-reference(s): 34
 ST monomethoxytrityl protective group DNA prep review;
 fluorenylmethoxycarbonyl protective group DNA prep review; phosphonic
 ester nucleic acid prep review; PNA DNA chimera prep review;
 polyamide nucleic acid DNA chimera review
 IT Protective groups
 (Fmoc/MMTr; prep. of **polyamide** nucleic acids,
 PNA/DNA-chimeras and phosphonic ester nucleic acids)
 IT Peptide nucleic acids
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (PNA/DNA-chimeras; prep. of **polyamide** nucleic acids,
 PNA/DNA-chimeras and phosphonic ester nucleic acids)
 IT DNA
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (PNA/DNA-chimeras; prep. of **polyamide** nucleic acids,
 PNA/DNA-chimeras, and phosphonic ester nucleic acids)
 IT Nucleic acids
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (phosphonic ester; prep. of **polyamide** nucleic acids,
 PNA/DNA-chimeras, and phosphonic ester nucleic acids)

=> d ibib abs hitstr 3

L12 ANSWER 3 OF 8 HCPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:412348 HCPLUS
DOCUMENT NUMBER: 127:66086
TITLE: Synthesis of **polyamide** nucleic acids using a
new protection scheme which is fully compatible with
oligonucleotide synthesis
AUTHOR(S): Breipohl, G.; Will, D.W.; Langner, D.;
Knolle, J.; Uhlmann, E.
CORPORATE SOURCE: Hoechst AG, Allgemeine Pharma Forschung G838,
Frankfurt am Main, D-65926, Germany
SOURCE: Innovation and Perspectives in Solid Phase Synthesis &
Combinatorial Libraries: Peptides, Proteins and
Nucleic Acids--Small Molecule Organic Chemical
Diversity, Collected Papers, International Symposium,
4th, Edinburgh, Sept. 12-16, 1995 (1996), Meeting Date
1995, 61-64. Editor(s): Epton, Roger. Mayflower
Scientific: Birmingham, UK.
CODEN: 64ONA9
DOCUMENT TYPE: Conference
LANGUAGE: English
AB A symposium on the prepn. of novel monomethoxytrityl (Mmt) protected
monomers for the prepn. of **polyamide** nucleic acids (PNAs) is
described. Use of the acid-labile Mmt group as temporary protection for
the primary amino function of aminoethylglycine in combination with
base-labile acyl-type protecting groups for the nucleobases allow a
synthetic strategy similar to std. oligo-nucleotide synthesis conditions.
PNAs of mixed base sequence have been synthesized with this method.

=> d ibib abs hitstr 4

L12 ANSWER 4 OF 8 HCPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1997:224058 HCPLUS
 DOCUMENT NUMBER: 126:274010
 TITLE: Recognition of Uncharged **Polyamide**-Linked
 Nucleic Acid Analogs by DNA Polymerases and Reverse
 Transcriptases
 AUTHOR(S): Lutz, Michael J.; Benner, Steven A.; Hein, Silvia;
Breipohl, Gerhard; Uhlmann, Eugen
 CORPORATE SOURCE: Department of Chemistry, Swiss Federal Institute of
 Technology, Zurich, CH-8092, Switz.
 SOURCE: Journal of the American Chemical Society (1997),
 119(13), 3177-3178
 CODEN: JACSAT; ISSN: 0002-7863
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB **Polyamide**-linked nucleic acid (PNAs) are DNA mimics in which the deoxyribose phosphate backbone is replaced by uncharged N-(2-aminoethyl)glycine units. Here, the authors report that several DNA polymerases and reverse transcriptases are able to elongate a PNA primer with a nucleophilic 3'-hydroxyl group, despite the fact that no phosphate residues are present in the PNA primer to interact with the polymerase. Enzymic synthesis of PNA-DNA chimeras might have implications for the use of modified PNAs in advanced diagnostic systems, allowing facilitated screening for genetic mutations, and as tools for studying structure-function relationships in enzymes that process nucleic acids. These results are also interesting in the light of models for the origin of life that propose an evolutionary linkage between a PNA-like and a DNA-protein world.

IT 9012-90-2, DNA polymerase
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)
 (I; recognition of uncharged DNA mimics (peptide nucleic acid primers)
 by DNA polymerases and reverse transcriptases)

RN 9012-90-2 HCPLUS

CN Nucleotidyltransferase, deoxyribonucleate (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9068-38-6, Reverse transcriptase 188901-47-5
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)
 (recognition of uncharged DNA mimics (peptide nucleic acid primers) by
 DNA polymerases and reverse transcriptases)

RN 9068-38-6 HCPLUS

CN Nucleotidyltransferase, deoxyribonucleate, RNA-dependent (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 188901-47-5 HCPLUS
 CN DNA, d(G-C-C-C-C-A-G-G-G-A-G-A-A-G-G-C-A-A-C-T-G-G-A-C-C-G-A-A-G-G-C-G-C-T-T-G-T-G-G-A-G-A-A-G-G-A-G-T-T-C-A-T-A-G-C-T-G-G-G-C-T-C-C-C-T-A-T-A-G-T-G-A-G-T-C-G-T-A-T-T-A), complex with peptide nucleic acid (H-T-A-A-T-A-C-G-A-C-T-C-A-C-T-A)-[2-(5'-thymidylylaminio)ethyl]NH (1:1) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


MAUPIN 09/835,371

=> d ibib abs hitstr 5


L12 ANSWER 5 OF 8 HCPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1996:508642 HCPLUS
 Correction of: 1996:190218
 DOCUMENT NUMBER: 125:168639
 Correction of: 124:344062
 TITLE: Synthesis of polyamide nucleic acids (PNAs)
 using a novel Fmoc/Mmt protecting-group combination
 AUTHOR(S): Breipohl, G.; Knolle, J.; Langner, D.;
 O'Malley, G.; Uhlmann, E.
 CORPORATE SOURCE: Central Pharma Res., Hoechst AG, Frankfurt, 65926,
 Germany
 SOURCE: Bioorg. Med. Chem. Lett. (1996), 6(6), 665-670
 CODEN: BMCLE8; ISSN: 0960-894X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The prepn. of 9-fluorenylmethoxycarbonyl (Fmoc) protected building blocks
 for the synthesis of polyamide nucleic acids (PNAs) is
 described. Use of 4-methoxyphenylidiphenylmethyl (Mmt)-protecting groups
 for the exocyclic amino function of the nucleobases enhances the solv. of
 the monomers and allows final deprotection by mild acid treatment. The
 novel synthetic route is exemplified by the synthesis of heptameric and
 octameric PNAs.
 IT 71-30-7, Cytosine 73-24-5, Adenine, reactions
 96-32-2, Methyl bromoacetate 10310-21-1,
 2-Amino-6-chloropurine 20924-05-4, 1-(Carboxymethyl)thymine
 172405-43-5
 RL: RCT (Reactant)
 (synthesis of peptide nucleic acids using a novel
 fluorenylmethoxycarbonyl and monomethoxytrityl protecting group
 combination)
 RN 71-30-7 HCPLUS
 CN 2(1H)-Pyrimidinone, 4-amino- (9CI) (CA INDEX NAME)




RN 73-24-5 HCPLUS
 CN 1H-Purin-6-amine (9CI) (CA INDEX NAME)




RN 96-32-2 HCPLUS
 CN Acetic acid, bromo-, methyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 10310-21-1 HCAPLUS
 CN 1H-Purin-2-amine, 6-chloro- (9CI) (CA INDEX NAME)



RN 20924-05-4 HCAPLUS
 CN 1(2H)-Pyrimidineacetic acid, 3,4-dihydro-5-methyl-2,4-dioxo- (8CI, 9CI)
 (CA INDEX NAME)



RN 172405-43-5 HCAPLUS
 CN Glycine, N-[2-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 169396-92-3P 172405-46-8P 172405-47-9P
 172405-48-0P 172405-49-1P 172405-50-4P
 172405-51-5P 172405-52-6P 172405-53-7P
 172405-54-8P 172405-55-9P 172405-56-0P
 172405-57-1P 172405-58-2P 172405-59-3P
 172405-62-8P 176750-53-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of peptide nucleic acids using a novel
 fluorenylmethoxycarbonyl and monomethoxytrityl protecting group
 combination)
 RN 169396-92-3 HCAPLUS
 CN Glycine, N-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N-[2-


MAUPIN 09/835,371

[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 172405-46-8 HCAPLUS
CN 9H-Purine-9-acetic acid, 2-amino-6-chloro-, methyl ester (9CI) (CA INDEX NAME)



RN 172405-47-9 HCAPLUS


MAUPIN 09/835,371

CN 9H-Purine-9-acetic acid, 6-chloro-2-[(4-methoxyphenyl)diphenylmethyl]amino-, methyl ester (9CI) (CA INDEX NAME)




RN 172405-48-0 HCAPLUS

CN 9H-Purine-9-acetic acid, 1,6-dihydro-2-[(4-methoxyphenyl)diphenylmethyl]amino]-6-oxo- (9CI) (CA INDEX NAME)




RN 172405-49-1 HCAPLUS

CN 1H-Purin-6-amine, N-[(4-methoxyphenyl)diphenylmethyl]- (9CI) (CA INDEX NAME)




RN 172405-50-4 HCAPLUS


CN 9H-Purine-9-acetic acid, 6-[(4-methoxyphenyl)diphenylmethyl]amino-, methyl ester (9CI) (CA INDEX NAME)



RN 172405-51-5 HCAPLUS


CN 9H-Purine-9-acetic acid, 6-[(4-methoxyphenyl)diphenylmethyl]amino- (9CI)
(CA INDEX NAME)

RN 172405-52-6 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-[(4-methoxyphenyl)diphenylmethyl]amino- (9CI) (CA
INDEX NAME)


RN 172405-53-7 HCAPLUS

CN 1(2H)-Pyrimidineacetic acid, 4-[(4-methoxyphenyl)diphenylmethyl]amino]-2-
oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 172405-54-8 HCAPLUS


CN 1(2H)-Pyrimidineacetic acid, 4-[[[(4-methoxyphenyl)diphenylmethyl]amino]-2-oxo- (9CI) (CA INDEX NAME)




RN 172405-55-9 HCAPLUS

CN Glycine, N-[[1,6-dihydro-2-[[[(4-methoxyphenyl)diphenylmethyl]amino]-6-oxo-9H-purin-9-yl]acetyl]-N-[2-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 172405-56-0 HCPLUS

CN Glycine, N-[2-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-N-[[6-[(4-methoxyphenyl)diphenylmethyl]amino]-9H-purin-9-yl]acetyl]-, methyl ester
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 172405-57-1 HCPLUS

CN Glycine, N-[2-[[9H-fluoren-9-ylmethoxy]carbonyl]amino]ethyl]-N-[[6-[[[(4-methoxyphenyl)diphenylmethyl]amino]-9H-purin-9-yl]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 172405-58-2 HCPLUS

CN Glycine, N-[2-[[[9H-fluoren-9-ylmethoxy]carbonyl]amino]ethyl]-N-[[4-[[[(4-methoxyphenyl)diphenylmethyl]amino]-2-oxo-1(2H)-pyrimidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 172405-59-3 HCAPLUS

CN Glycine, N-[2-[[9H-fluoren-9-ylmethoxy]carbonyl]amino]ethyl]-N-[[4-[(4-methoxyphenyl)diphenylmethyl]amino]-2-oxo-1(2H)-pyrimidinyl]acetyl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 172405-62-8 HCAPLUS

CN Glycine, N-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N-[2-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 176750-53-1 HCAPLUS

CN Glycine, N-[[1,6-dihydro-2-[(4-methoxyphenyl)diphenylmethyl]amino]-6-oxo-9H-purin-9-yl]acetyl]-N-[2-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 139166-84-0P 172405-67-3P 176750-54-2P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of peptide nucleic acids using a novel
 fluorenlymethoxycarbonyl and monomethoxytrityl protecting group
 combination)

RN 139166-84-0 HCAPLUS


CN Peptide nucleic acid, (H-T-T-T-T-T-T-T-T)-Lys-NH₂ (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C




RN 172405-67-3 HCPLUS


CN Peptide nucleic acid, (H-C-C-C-C-C-C-C)-Lys-NH2 (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C




RN 176750-54-2 HCPLUS

CN 9H-Purine-9-acetamide, 2-amino-N-[24-[(6-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)acetyl]-6,12,18-tris[(6-amino-9H-purin-9-yl)acetyl]-4,10,16,22,28-pentaoxo-3,6,9,12,15,18,21,24,27-nonaazanonacos-1-yl]-N-[6,12,18,24-tetrakis[(6-amino-9H-purin-9-yl)acetyl]-33-hydroxy-2,8,14,20,26-pentaoxo-3,6,9,12,15,18,21,24,27-nonaazatritriacont-1-yl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



MAUPIN 09/835, 371


PAGE 1-C



PAGE 1-D

— CH_2-NHAc

PAGE 2-C




=> d ind 5

L12 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2002 ACS
 CC 34-3 (Amino Acids, Peptides, and Proteins)
 Section cross-reference(s): 26
 ST **polyamide** nucleic acid Merrifield synthesis; peptide nucleic acid Merrifield synthesis; monomethoxytrityl nucleobase protective group solv
 IT Merrifield synthesis
 (synthesis of peptide nucleic acids using a novel fluorenylmethoxycarbonyl and monomethoxytrityl protecting group combination)
 IT Peptide nucleic acids
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of peptide nucleic acids using a novel fluorenylmethoxycarbonyl and monomethoxytrityl protecting group combination)
 IT Protective groups
 (methoxytrityl, synthesis of peptide nucleic acids using a novel fluorenylmethoxycarbonyl and monomethoxytrityl protecting group combination)
 IT **71-30-7**, Cytosine **73-24-5**, Adenine, reactions
96-32-2, Methyl bromoacetate **10310-21-1**,
 2-Amino-6-chloropurine **20924-05-4**, 1-(Carboxymethyl)thymine
172405-43-5
 RL: RCT (Reactant)
 (synthesis of peptide nucleic acids using a novel fluorenylmethoxycarbonyl and monomethoxytrityl protecting group combination)
 IT **169396-92-3P** **172405-46-8P** **172405-47-9P**
172405-48-0P **172405-49-1P** **172405-50-4P**
172405-51-5P **172405-52-6P** **172405-53-7P**
172405-54-8P **172405-55-9P** **172405-56-0P**
172405-57-1P **172405-58-2P** **172405-59-3P**
172405-62-8P **176750-53-1P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of peptide nucleic acids using a novel fluorenylmethoxycarbonyl and monomethoxytrityl protecting group combination)
 IT **139166-84-0P** **172405-67-3P** **176750-54-2P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of peptide nucleic acids using a novel fluorenylmethoxycarbonyl and monomethoxytrityl protecting group combination)


MAUPIN 09/835,371

=> d ibib abs hitstr 6


L12 ANSWER 6 OF 8 HCPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1996:190218 HCPLUS
 DOCUMENT NUMBER: 124:344062
 TITLE: Synthesis of **polyamide** nucleic acids (PNAs)
 using a novel Fmoc/Mmt protecting-group combination
 AUTHOR(S): Breipohol, G.; Knolle, J.; Langner, D.; O'Malley, G.;
Uhlmann, E.
 CORPORATE SOURCE: Central Pharma Research, Hoechst AG, Frankfurt, 65926,
 Germany
 SOURCE: Bioorg. Med. Chem. Lett. (1996), 6(6), 665-70
 CODEN: BMCLE8; ISSN: 0960-894X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The prepn. of 9-fluorenylmethoxycarbonyl (Fmoc) protected building blocks
 for the synthesis of **polyamide** nucleic acids (PNAs) is
 described. Use of 4-methoxyphenyldiphenylmethyl (Mmt)-protecting groups.
 for the exocyclic amino function of the nucleobases enhances the solv. of
 the monomers and allows final deprotection by mild acid treatment. The
 novel synthetic route is exemplified by the synthesis of heptameric and
 octameric PNAs.
 IT 71-30-7, Cytosine 73-24-5, Adenine, reactions
 96-32-2, Methyl bromoacetate 10310-21-1,
 2-Amino-6-chloropurine 20924-05-4, 1-(Carboxymethyl)thymine
172405-43-5
 RL: RCT (Reactant)
 (synthesis of peptide nucleic acids using a novel
 fluorenylmethoxycarbonyl and monomethoxytrityl protecting group
 combination)
 RN 71-30-7 HCPLUS
 CN 2(1H)-Pyrimidinone, 4-amino- (9CI) (CA INDEX NAME)




RN 73-24-5 HCPLUS
 CN 1H-Purin-6-amine (9CI) (CA INDEX NAME)




RN 96-32-2 HCPLUS
 CN Acetic acid, bromo-, methyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 10310-21-1 HCAPLUS
 CN 1H-Purin-2-amine, 6-chloro- (9CI) (CA INDEX NAME)



RN 20924-05-4 HCAPLUS
 CN 1(2H)-Pyrimidineacetic acid, 3,4-dihydro-5-methyl-2,4-dioxo- (8CI, 9CI)
 (CA INDEX NAME)



RN 172405-43-5 HCAPLUS
 CN Glycine, N-[2-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 169396-92-3P 172405-46-8P 172405-47-9P
 172405-48-0P 172405-49-1P 172405-50-4P
 172405-51-5P 172405-52-6P 172405-53-7P
 172405-54-8P 172405-55-9P 172405-56-0P
 172405-57-1P 172405-58-2P 172405-59-3P
 172405-62-8P 176750-53-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of peptide nucleic acids using a novel
 fluorenylmethoxycarbonyl and monomethoxytrityl protecting group
 combination)

RN 169396-92-3 HCAPLUS


MAUPIN 09/835, 371

CN Glycine, N-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 172405-46-8 HCPLUS


CN 9H-Purine-9-acetic acid, 2-amino-6-chloro-, methyl ester (9CI) (CA INDEX NAME)




RN 172405-47-9 HCAPLUS
 CN 9H-Purine-9-acetic acid, 6-chloro-2-[(4-methoxyphenyl)diphenylmethyl]amino-, methyl ester (9CI) (CA INDEX NAME)




RN 172405-48-0 HCAPLUS
 CN 9H-Purine-9-acetic acid, 1,6-dihydro-2-[(4-methoxyphenyl)diphenylmethyl]amino]-6-oxo- (9CI) (CA INDEX NAME)




RN 172405-49-1 HCAPLUS
 CN 1H-Purin-6-amine, N-[(4-methoxyphenyl)diphenylmethyl]- (9CI) (CA INDEX NAME)




RN 172405-50-4 HCAPLUS
 CN 9H-Purine-9-acetic acid, 6-[(4-methoxyphenyl)diphenylmethyl]amino-, methyl ester (9CI) (CA INDEX NAME)



RN 172405-51-5 HCAPLUS


CN 9H-Purine-9-acetic acid, 6-[(4-methoxyphenyl)diphenylmethyl]amino]- (9CI)
(CA INDEX NAME)

RN 172405-52-6 HCAPLUS

CN 2(1H)-Pyrimidinone, 4-[(4-methoxyphenyl)diphenylmethyl]amino]- (9CI) (CA
INDEX NAME)


RN 172405-53-7 HCAPLUS

CN 1(2H)-Pyrimidineacetic acid, 4-[(4-methoxyphenyl)diphenylmethyl]amino]-2-
oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 172405-54-8 HCAPLUS


CN 1(2H)-Pyrimidineacetic acid, 4-[[[(4-methoxyphenyl)diphenylmethyl]amino]-2-oxo- (9CI) (CA INDEX NAME)




RN 172405-55-9 HCAPLUS

CN Glycine, N-[[1,6-dihydro-2-[[[(4-methoxyphenyl)diphenylmethyl]amino]-6-oxo-9H-purin-9-yl]acetyl]-N-[2-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 172405-56-0 HCAPLUS

CN Glycine, N-[2-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-N-[[6-[(4-methoxyphenyl)diphenylmethyl]amino]-9H-purin-9-yl]acetyl]-, methyl ester
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 172405-57-1 HCAPLUS

CN Glycine, N-[2-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-N-[[6-[(4-methoxyphenyl)diphenylmethyl]amino]-9H-purin-9-yl]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 172405-58-2 HCPLUS

CN Glycine, N-[2-[[[9H-fluoren-9-ylmethoxy]carbonyl]amino]ethyl]-N-[[4-[(4-methoxyphenyl)diphenylmethyl]amino]-2-oxo-1(2H)-pyrimidinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 172405-59-3 HCAPLUS

CN Glycine, N-[2-[[[9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-N-[[4-[(4-methoxyphenyl)diphenylmethyl]amino]-2-oxo-1(2H)-pyrimidinyl]acetyl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 172405-62-8 HCAPLUS
 CN Glycine, N-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N-[2-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 176750-53-1 HCAPLUS

CN Glycine, N-[[1,6-dihydro-2-[(4-methoxyphenyl)diphenylmethyl]amino]-6-oxo-9H-purin-9-yl]acetyl]-N-[2-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 139166-84-0P 172405-67-3P 176750-54-2P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of peptide nucleic acids using a novel
 fluorenlymethoxycarbonyl and monomethoxytrityl protecting group
 combination)

RN 139166-84-0 HCAPLUS


CN Peptide nucleic acid, (H-T-T-T-T-T-T-T-T)-Lys-NH₂ (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C




RN 172405-67-3 HCPLUS


CN Peptide nucleic acid, (H-C-C-C-C-C-C-C)-Lys-NH2 (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C




RN 176750-54-2 HCPLUS

CN 9H-Purine-9-acetamide, 2-amino-N-[24-[(6-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)acetyl]-6,12,18-tris[(6-amino-9H-purin-9-yl)acetyl]-4,10,16,22,28-pentaoxo-3,6,9,12,15,18,21,24,27-nonaazanonacos-1-yl]-N-[6,12,18,24-tetrakis[(6-amino-9H-purin-9-yl)acetyl]-33-hydroxy-2,8,14,20,26-pentaoxo-3,6,9,12,15,18,21,24,27-nonaazatritriacont-1-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



MAUPIN 09/835, 371


PAGE 1-C



PAGE 1-D

$-\text{CH}_2-\text{NHAc}$

PAGE 2-C



=> d ind 6

L12 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2002 ACS
 CC 34-3 (Amino Acids, Peptides, and Proteins)
 Section cross-reference(s): 26

ST **polyamide** nucleic acid Merrifield synthesis; peptide nucleic acid Merrifield synthesis; monomethoxytrityl nucleobase protective group solv

IT Merrifield synthesis
 (synthesis of peptide nucleic acids using a novel fluorenylmethoxycarbonyl and monomethoxytrityl protecting group combination)

IT Peptide nucleic acids
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of peptide nucleic acids using a novel fluorenylmethoxycarbonyl and monomethoxytrityl protecting group combination)

IT Protective groups
 (methoxytrityl, synthesis of peptide nucleic acids using a novel fluorenylmethoxycarbonyl and monomethoxytrityl protecting group combination)

IT **71-30-7**, Cytosine **73-24-5**, Adenine, reactions
96-32-2, Methyl bromoacetate **10310-21-1**,
 2-Amino-6-chloropurine **20924-05-4**, 1-(Carboxymethyl)thymine
172405-43-5
 RL: RCT (Reactant)
 (synthesis of peptide nucleic acids using a novel fluorenylmethoxycarbonyl and monomethoxytrityl protecting group combination)

IT **169396-92-3P** **172405-46-8P** **172405-47-9P**
172405-48-0P **172405-49-1P** **172405-50-4P**
172405-51-5P **172405-52-6P** **172405-53-7P**
172405-54-8P **172405-55-9P** **172405-56-0P**
172405-57-1P **172405-58-2P** **172405-59-3P**
172405-62-8P **176750-53-1P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of peptide nucleic acids using a novel fluorenylmethoxycarbonyl and monomethoxytrityl protecting group combination)

IT **139166-84-0P** **172405-67-3P** **176750-54-2P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of peptide nucleic acids using a novel fluorenylmethoxycarbonyl and monomethoxytrityl protecting group combination)

MAUPIN 09/835,371

=> d ibib abs hitstr 7

L12 ANSWER 7 OF 8 HCPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1995:994444 HCPLUS
 DOCUMENT NUMBER: 124:202955
 TITLE: Preparation of **polyamide**-oligonucleotide derivatives as drugs, gene probes, and primers.
 INVENTOR(S): Uhlmann, Eugen; Breipohl, Gerhard
 PATENT ASSIGNEE(S): Hoechst A.-G., Germany
 SOURCE: Eur. Pat. Appl., 51 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 672677	A2	19950920	EP 1995-103332	19950308
EP 672677	A3	19960117		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 4408528	A1	19950928	DE 1994-4408528	19940314
EP 1113021	A2	20010704	EP 2001-104012	19950308
EP 1113021	A3	20010711		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
FI 9501132	A	19950915	FI 1995-1132	19950310
AU 9514798	A1	19950921	AU 1995-14798	19950310
AU 698210	B2	19981029		
CA 2144475	AA	19950915	CA 1995-2144475	19950313
NO 9500955	A	19950915	NO 1995-955	19950313
CN 1112126	A	19951122	CN 1995-102946	19950313
JP 07278179	A2	19951024	JP 1995-54644	19950314
PRIORITY APPLN. INFO.:			DE 1994-4408528	A 19940314
			EP 1995-103332	A3 19950308

AB F[(QB)q(Q1B)r(Q2B)s(Q3B)t]xF1 [q, r, s, t = 0, 1; X = 1-20; Q, Q2 = nucleic acid (deriv.); Q1, Q3 = **polyamide** residue contg. .gtoreq.1 nucleic acid base except thymine; B = covalent bond, org. residue contg. .gtoreq.1 of C, N, O, S; F, F1 = end groups which may be bound to each other], were prepnd. Title compds. show increased cellular uptake, improved nuclease stability, and are not cytotoxic; they are claimed for use as drugs and gene probes.

IT 175864-54-7P 175864-55-8P
 RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of **polyamide**-oligonucleotide derivs. as drugs, gene probes, and primers)

RN 175864-54-7 HCPLUS
 CN DNA, d(A-T-C-G-T-C-G-T-A-T-T-[oxyphosphinicoxy(4-oxo-1,4-butanediyl)]pC-pC-(6-hydroxyhexyl)NH (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 175864-55-8 HCPLUS
 CN DNA, d(A-T-C-G-T-C-G-T-A-T-T-(5'-deamino-5'-oxy)pT-pC-pC-pC)-(6-hydroxyhexyl)NH (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 IT 108-30-5, reactions 502-85-2 4048-33-3,
 6-Amino-1-hexanol 20924-05-4 67826-12-4

98796-51-1 100747-20-4 172405-39-9

172405-41-3 172405-42-4 172494-26-7


172494-27-8 172494-28-9

RL: RCT (Reactant)

(prepn. of polyamide-oligonucleotide derivs. as drugs, gene probes, and primers)

RN 108-30-5 HCPLUS

CN 2,5-Furandione, dihydro- (9CI) (CA INDEX NAME)



RN 502-85-2 HCPLUS

CN Butanoic acid, 4-hydroxy-, monosodium salt (9CI) (CA INDEX NAME)

 $\text{HO}-(\text{CH}_2)_3-\text{CO}_2\text{H}$


● Na

RN 4048-33-3 HCPLUS


CN 1-Hexanol, 6-amino- (6CI, 8CI, 9CI) (CA INDEX NAME)

 $\text{H}_2\text{N}-(\text{CH}_2)_6-\text{OH}$

RN 20924-05-4 HCPLUS

CN 1(2H)-Pyrimidineacetic acid, 3,4-dihydro-5-methyl-2,4-dioxo- (8CI, 9CI)
(CA INDEX NAME)


RN 67826-12-4 HCPLUS

CN 1(2H)-Pyrimidineacetyl chloride, 3,4-dihydro-5-methyl-2,4-dioxo- (9CI)
(CA INDEX NAME)

RN 98796-51-1 HCPLUS

CN Thymidine, 5'-O-[bis(4-methoxyphenyl)phenylmethyl]-, 3'-[2-cyanoethyl bis(1-methylethyl)phosphoramidite] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 100747-20-4 HCAPLUS

CN Glycine, N-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)

HO—(CH₂)₃—NH—CH₂—CO₂H


RN 172405-39-9 HCAPLUS

CN Glycine, N-[6-[(4-methoxybenzoyl)amino]-9H-purin-9-yl]acetyl]-N-[2-[(4-methoxyphenyl)diphenylmethyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 172405-41-3 HCAPLUS

CN Glycine, N-[1,6-dihydro-2-[(2-methyl-1-oxopropyl)amino]-6-oxo-9H-purin-9-yl]acetyl]-N-[2-[(4-methoxyphenyl)diphenylmethyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 172405-42-4 HCAPLUS

CN Glycine, N-[4-[[4-(1,1-dimethylethyl)benzoyl]amino]-2-oxo-1(2H)-pyrimidinyl]acetyl]-N-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 172494-26-7 HCAPLUS

CN Glycine, N-[2-[(4-methoxyphenyl)diphenylmethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 172494-27-8 HCAPLUS

CN Glycine, N-(4-hydroxybutyl)- (9CI) (CA INDEX NAME)

HO-(CH₂)₄-NH-CH₂-CO₂H

RN 172494-28-9 HCAPLUS

CN Glycine, N-(5-hydroxypentyl)- (9CI) (CA INDEX NAME)

HO-(CH₂)₅-NH-CH₂-CO₂H

IT 114729-83-8P 125697-62-3P 172316-34-6DP, resin

bound 172316-34-6P 172316-40-4P 172316-42-6P


172316-45-9P 172405-31-1P 172494-29-0P

172494-30-3P 172494-31-4P 172494-32-5P


172494-33-6P 172494-34-7P 172494-35-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of polyamide-oligonucleotide derivs. as drugs, gene probes, and primers)


RN 114729-83-8 HCAPLUS
 CN 1-Hexanol, 6-[[[4-methoxyphenyl)diphenylmethyl]amino]- (9CI) (CA INDEX NAME)




RN 125697-62-3 HCAPLUS
 CN Butanoic acid, 4-[bis(4-methoxyphenyl)phenylmethoxy]-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)




RN 172316-34-6 HCAPLUS
 CN Butanedioic acid, mono[6-[[[4-methoxyphenyl)diphenylmethyl]amino]hexyl] ester (9CI) (CA INDEX NAME)



RN 172316-34-6 HCAPLUS
 CN Butanedioic acid, mono[6-[[[4-methoxyphenyl)diphenylmethyl]amino]hexyl] ester (9CI) (CA INDEX NAME)




RN 172316-40-4 HCAPLUS
 CN Glycine, N-[[6-[(4-methoxybenzoyl)amino]-9H-purin-9-yl]acetyl]-N-[2-[[[4-methoxyphenyl)diphenylmethyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 172316-42-6 HCAPLUS

CN Glycine, N-[(1,6-dihydro-2-[(2-methyl-1-oxopropyl)amino]-6-oxo-9H-purin-9-yl]acetyl]-N-[2-[(4-methoxyphenyl)diphenylmethyl]amino]ethyl- (9CI) (CA INDEX NAME)




RN 172316-45-9 HCAPLUS

CN Glycine, N-[[4-[(1,1-dimethylethyl)benzoyl]amino]-2-oxo-1(2H)-pyrimidinyl]acetyl]-N-[2-[(4-methoxyphenyl)diphenylmethyl]amino]ethyl- (9CI) (CA INDEX NAME)




RN 172405-31-1 HCAPLUS

CN Glycine, N-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N-[2-[(4-methoxyphenyl)diphenylmethoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 172494-29-0 HCAPLUS

CN Glycine, N-[(4-amino-2-oxo-1(2H)-pyrimidinyl)acetyl]-N-[2-[(4-methoxyphenyl)diphenylmethyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 172494-30-3 HCAPLUS

CN Glycine, N-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)




RN 172494-31-4 HCAPLUS

CN Glycine, N-[3-[bis(4-methoxyphenyl)phenylmethoxy]propyl]-N-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 172494-32-5 HCAPLUS

CN Glycine, N-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N-(4-hydroxybutyl)- (9CI) (CA INDEX NAME)




RN 172494-33-6 HCAPLUS

CN Glycine, N-[4-[bis(4-methoxyphenyl)phenylmethoxy]butyl]-N-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 172494-34-7 HCAPLUS

CN Glycine, N-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N-(5-hydroxypentyl)- (9CI) (CA INDEX NAME)



RN 172494-35-8 HCAPLUS

CN Glycine, N-[5-[bis(4-methoxyphenyl)phenylmethoxy]pentyl]-N-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]- (9CI) (CA INDEX NAME)



=> d ind 7

L12 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2002 ACS

IC ICM C07H021-00

ICS C08L077-00; C12Q001-68; A61K031-70

CC 33-9 (Carbohydrates)

Section cross-reference(s): 1, 6, 34

ST polyamide oligonucleotide prep drug probe primer; dna pna hybrid mol prep; gene probe polyamide oligonucleotide prep

IT Neoplasm inhibitors

Nucleic acid hybridization

Virucides and Virustats
 (prepn. of **polyamide**-oligonucleotide derivs. as drugs, gene probes, and primers)

IT Nucleopeptides
 RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of **polyamide**-oligonucleotide derivs. as drugs, gene probes, and primers)

IT Animal cell
 (treatment of diseases influenced by cell-cell adhesion receptors; prepn. of **polyamide**-oligonucleotide derivs. as drugs, gene probes, and primers)

IT Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (treatment of diseases influenced by integrins; prepn. of **polyamide**-oligonucleotide derivs. as drugs, gene probes, and primers)

IT Nucleotides, preparation
 RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (oligo-, prepn. of **polyamide**-oligonucleotide derivs. as drugs, gene probes, and primers)

IT Nucleotides, preparation
 RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (oligo-, deoxyribo-, prepn. of **polyamide**-oligonucleotide derivs. as drugs, gene probes, and primers)

IT Heart, disease
 (restenosis, treatment; prepn. of **polyamide**-oligonucleotide derivs. as drugs, gene probes, and primers)


IT 175864-54-7P 175864-55-8P
 RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of **polyamide**-oligonucleotide derivs. as drugs, gene probes, and primers)

IT 108-30-5, reactions 502-85-2 4048-33-3,
 6-Amino-1-hexanol 20924-05-4 67826-12-4
 98796-51-1 100747-20-4 172405-39-9
 172405-41-3 172405-42-4 172494-26-7
 172494-27-8 172494-28-9
 RL: RCT (Reactant)
 (prepn. of **polyamide**-oligonucleotide derivs. as drugs, gene probes, and primers)


IT 114729-83-8P 125697-62-3P 172316-34-6DP, resin
 bound 172316-34-6P 172316-40-4P 172316-42-6P
 172316-45-9P 172405-31-1P 172494-29-0P
 172494-30-3P 172494-31-4P 172494-32-5P
 172494-33-6P 172494-34-7P 172494-35-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of **polyamide**-oligonucleotide derivs. as drugs, gene probes, and primers)

=> d ibib abs hitstr 8


L12 ANSWER 8 OF 8 HCPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1995:908968 HCPLUS
 DOCUMENT NUMBER: 124:117857
 TITLE: The synthesis of **polyamide** nucleic acids
 using a novel monomethoxytrityl protecting-group
 strategy
 AUTHOR(S): Will, David W.; Breipohl, Gerhard; Langner,
 Dietrich; Knolle, Jochen; Uhlmann, Eugen
 CORPORATE SOURCE: Hoechst AG, Allgemeine Pharma Forschung G838,
 Frankfurt am Main, D-65926, Germany
 SOURCE: Tetrahedron (1995), 51(44), 12069-82
 CODEN: TETRAB; ISSN: 0040-4020
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 124:117857
 AB The prepn. of 4-MeOC₆H₄CPh₂NHCH₂CH₂(COCH₂R)CH₂CO₂Me (R = thymine,
 N4-tert-butylbenzoylcytosine, N6-anisoyladenine, N2-isobutanoylguanine)
 for the synthesis of **polyamide** nucleic acids (PNAs) is
 described. The use of base-labile acyl-type nucleobase protecting groups,
 including monomethyltrityl N-protection of H₂NCH₂CH₂NhCH₂CO₂Me, and of a
 succinyl-linked solid-support offers a synthetic strategy similar to std.
 oligonucleotide synthesis conditions. This strategy has been successfully
 applied for the synthesis of PNAs of mixed base sequence.
 IT 71-30-7, Cytosine 73-24-5, Adenine, reactions
 73-40-5 96-32-2, Methyl bromoacetate 107-15-3,
 1,2-Ethanediamine, reactions 298-12-4 1710-98-1,
 4-tert-Butylbenzoyl chloride 4048-33-3, 6-Aminohexan-1-ol
20924-05-4
 RL: RCT (Reactant)
 (synthesis of **polyamide** nucleic acid analogs from
 monomethoxytrityl-protected aminoethylglycine)
 RN 71-30-7 HCPLUS
 CN 2(1H)-Pyrimidinone, 4-amino- (9CI) (CA INDEX NAME)




RN 73-24-5 HCPLUS
 CN 1H-Purin-6-amine (9CI) (CA INDEX NAME)




RN 73-40-5 HCPLUS
 CN 6H-Purin-6-one, 2-amino-1,7-dihydro- (9CI) (CA INDEX NAME)




RN 96-32-2 HCAPLUS
 CN Acetic acid, bromo-, methyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 107-15-3 HCAPLUS
 CN 1,2-Ethanediamine (9CI) (CA INDEX NAME)




RN 298-12-4 HCAPLUS
 CN Acetic acid, oxo- (9CI) (CA INDEX NAME)




RN 1710-98-1 HCAPLUS
 CN Benzoyl chloride, 4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 4048-33-3 HCAPLUS
 CN 1-Hexanol, 6-amino- (6CI, 8CI, 9CI) (CA INDEX NAME)




RN 20924-05-4 HCAPLUS
 CN 1(2H)-Pyrimidineacetic acid, 3,4-dihydro-5-methyl-2,4-dioxo- (8CI, 9CI)
 (CA INDEX NAME)




IT 18907-79-4P 21047-89-2P 24123-14-6P,
 N-(2-Aminoethyl)glycine 97025-97-3P 114729-83-8P
 135697-25-5P 170944-06-6P 172316-34-6DP,
 polymer bound 172316-34-6P 172316-36-8P
 172316-40-4P 172316-42-6P 172316-45-9P
 172405-11-7P 172405-12-8P 172405-17-3P
 172405-18-4P 172405-19-5P 172405-20-8P
 172405-21-9P 172405-39-9P 172405-41-3P
 172405-42-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of **polyamide** nucleic acid analogs from
 monomethoxytrityl-protected aminoethylglycine)

RN 18907-79-4 HCPLUS
 CN Glycine, N-(2-aminoethyl)-, methyl ester, dihydrochloride (8CI, 9CI) (CA INDEX NAME)




●2 HCl


RN 21047-89-2 HCPLUS
 CN Propanamide, N-(6,7-dihydro-6-oxo-1H-purin-2-yl)-2-methyl- (9CI) (CA INDEX NAME)




RN 24123-14-6 HCPLUS
 CN Glycine, N-(2-aminoethyl)- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 97025-97-3 HCPLUS
 CN Benzamide, 4-methoxy-N-1H-purin-6-yl- (9CI) (CA INDEX NAME)




RN 114729-83-8 HCAPLUS
 CN 1-Hexanol, 6-[(4-methoxyphenyl)diphenylmethyl]amino- (9CI) (CA INDEX NAME)



RN 135697-25-5 HCAPLUS
 CN Benzamide, N-(1,2-dihydro-2-oxo-4-pyrimidinyl)-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 170944-06-6 HCAPLUS
 CN Glycine, N-[(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N-[2-[(4-methoxyphenyl)diphenylmethyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 172316-34-6 HCAPLUS

CN Butanedioic acid, mono[6-[(4-methoxyphenyl)diphenylmethyl]amino]hexyl ester (9CI) (CA INDEX NAME)




RN 172316-34-6 HCAPLUS

CN Butanedioic acid, mono[6-[(4-methoxyphenyl)diphenylmethyl]amino]hexyl ester (9CI) (CA INDEX NAME)




RN 172316-36-8 HCAPLUS

CN Glycine, N-[{(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)acetyl]-N-[2-[(4-methoxyphenyl)diphenylmethyl]amino]ethyl]-(9CI) (CA INDEX NAME)




RN 172316-40-4 HCAPLUS

CN Glycine, N-[{6-[(4-methoxybenzoyl)amino]-9H-purin-9-yl}acetyl]-N-[2-[(4-methoxyphenyl)diphenylmethyl]amino]ethyl]-(9CI) (CA INDEX NAME)




RN 172316-42-6 HCAPLUS

CN Glycine, N-[1,6-dihydro-2-[(2-methyl-1-oxopropyl)amino]-6-oxo-9H-purin-9-yl]acetyl]-N-[2-[(4-methoxyphenyl)diphenylmethyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 172316-45-9 HCAPLUS

CN Glycine, N-[4-[(4-(1,1-dimethylethyl)benzoyl)amino]-2-oxo-1(2H)-pyrimidinyl]acetyl]-N-[2-[(4-methoxyphenyl)diphenylmethyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 172405-11-7 HCAPLUS


CN 1(2H)-Pyrimidineacetic acid, 4-[(4-(1,1-dimethylethyl)benzoyl)amino]-2-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 172405-12-8 HCAPLUS

CN 1(2H)-Pyrimidineacetic acid, 4-[[4-(1,1-dimethylethyl)benzoyl]amino]-2-oxo-
(9CI) (CA INDEX NAME)

RN 172405-17-3 HCAPLUS


CN 9H-Purine-9-acetic acid, 6-[(4-methoxybenzoyl)amino]-, methyl ester (9CI)
(CA INDEX NAME)

RN 172405-18-4 HCAPLUS

CN 9H-Purine-9-acetic acid, 6-[(4-methoxybenzoyl)amino]- (9CI) (CA INDEX
NAME)


RN 172405-19-5 HCAPLUS

CN 9H-Purine-9-acetic acid, 1,6-dihydro-2-[(2-methyl-1-oxopropyl)amino]-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 172405-20-8 HCAPLUS

CN 9H-Purine-9-acetic acid, 1,6-dihydro-2-[(2-methyl-1-oxopropyl)amino]-6-oxo-, (9CI) (CA INDEX NAME)




RN 172405-21-9 HCAPLUS

CN Glycine, N-[2-[(4-methoxyphenyl)diphenylmethyl]amino]ethyl-, methyl ester (9CI) (CA INDEX NAME)




RN 172405-39-9 HCAPLUS

CN Glycine, N-[[6-[(4-methoxybenzoyl)amino]-9H-purin-9-yl]acetyl]-N-[2-[(4-methoxyphenyl)diphenylmethyl]amino]ethyl-, methyl ester (9CI) (CA INDEX NAME)




RN 172405-41-3 HCAPLUS

CN Glycine, N-[[1,6-dihydro-2-[(2-methyl-1-oxopropyl)amino]-6-oxo-9H-purin-9-yl]acetyl]-N-[2-[(4-methoxyphenyl)diphenylmethyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 172405-42-4 HCAPLUS

CN Glycine, N-[[4-[(4-(1,1-dimethylethyl)benzoyl)amino]-2-oxo-1(2H)-pyrimidinyl]acetyl]-N-[2-[(4-methoxyphenyl)diphenylmethyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)





IT 172316-39-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of polyamide nucleic acid analogs from monomethoxytrityl-protected aminoethylglycine)


RN 172316-39-1 HCAPLUS

CN Peptide nucleic acid, (H-A-C-A-T-C-A-T-G-G-T-C-G)-(6-hydroxyhexyl)NH (9CI)
(CA INDEX NAME)


PAGE 1-A




PAGE 2-A



PAGE 3-A




PAGE 3-B




MAUPIN 09/835, 371


PAGE 3-C




PAGE 4-A




PAGE 4-B



PAGE 4-C



PAGE 4 - D



=> d ind 8

L12 ANSWER 8 OF 8 HCPLUS COPYRIGHT 2002 ACS

CC 33-9 (Carbohydrates)

ST polyamide nucleic acid analog prepn; monomethoxytrityl amine protecting group aminoethylglycine; solid phase synthesis polyamide oligonucleotide analog

IT Nucleic acids

RL: SPN (Synthetic preparation); PREP (Preparation
(analogs, synthesis of **polyamide** nucleic acid analogs from
monomethoxytrityl-protected aminoethylglycine)

IT Protective groups

(methoxytrityl, for amine in aminoethylglycine)

IT 71-30-7, Cytosine 73-24-5, Adenine, reactions

73-40-5 96-32-2, Methyl bromoacetate 107-15-3,

1,2-Ethanediamine, reactions 298-12-4 1710-98-1,

4-tert-Butyl-

20924-05-4
RL: RCT (Reactant)
(synthesis of polyamide nucleic acid analogs from

monomethoxytrityl-protected aminoethylglycine)
IT 18907-79-4P 21047-89-2P 24123-14-6P,
N-(2-Aminoethyl)glycine 97025-97-3P 114729-83-8P
135697-25-5P 170944-06-6P 172316-34-6DP,
polymer bound 172316-34-6DP, polymer-bound 172316-34-6P
172316-36-8P 172316-40-4P 172316-42-6P
172316-45-9P 172405-11-7P 172405-12-8P

MAUPIN 09/835,371

172405-17-3P 172405-18-4P 172405-19-5P

172405-20-8P 172405-21-9P 172405-39-9P

172405-41-3P 172405-42-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(synthesis of **polyamide** nucleic acid analogs from
monomethoxytrityl-protected aminoethylglycine)

IT 172316-39-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of **polyamide** nucleic acid analogs from
monomethoxytrityl-protected aminoethylglycine)